Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal anti-VEGF with or without dexamethasone for diabetic macular edema
RBR-7468j4qPhase 2Not yet recruiting
- Sponsor
- Universidade Federal de Pernambuco
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ranibizumab, aflibercept and dexamethasone in diabetic macular edema (DME) (4 arms), sponsored by Universidade Federal de Pernambuco. Primary endpoints: Central macular thickness at 90 days and Best-corrected visual acuity at 90 days. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
ranibizumabafliberceptdexamethasone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on RBR-7468j4q.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7468j4q.